Literature DB >> 32589376

Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with the varying activity of inflammatory bowel disease.

Dorota Cibor1, Katarzyna Szczeklik2, Kamil Kozioł3, Halina Pocztar3, Tomasz Mach3, Danuta Owczarek3.   

Abstract

INTRODUCTION: Endothelial dysfunction leads to an increased expression of cell adhesion molecules, leukocyte diapedesis, vascular smooth‑muscle tone, excessive permeability of vascular walls, and increased procoagulant activity.
OBJECTIVES: We investigated whether serum levels of several endothelial and platelet activation markers correlated with disease activity in patients with inflammatory bowel disease (IBD). PATIENTS AND METHODS: This study included 56 patients with ulcerative colitis, 66 with Crohn disease, and 40 healthy controls. We measured the complete blood count and levels of fibrinogen, C‑reactive protein, albumin, interleukin 6, tumor necrosis factor α, E‑selectin, P‑selectin, monocyte chemoattractant protein 1 (MCP‑1), soluble CD40 ligand (sCD40L), and microparticles.
RESULTS: There were no significant differences in the median levels of E‑selectin, P‑selectin, MCP‑1, sCD40L, and microparticles between patients with active IBD, those with inactive IBD, and healthy controls. The clinical disease activity assessed with the Mayo scale in the ulcerative‑colitis group was weakly, positively correlated with sCD40L (R = 0.32, P = 0.02), P‑selectin (R = 0.32, P = 0.02), and inflammatory marker levels. The clinical disease activity index in the Crohn disease group was positively correlated with the markers of inflammation yet not with the markers of endothelial activity.
CONCLUSIONS: E‑selectin, P‑selectin, sCD40L, MCP‑1, and microparticle levels do not significantly differ between patients with the varying activity of IBD. However, due to the observed correlations, further studies of a larger patient group should be conducted to confirm our observations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32589376     DOI: 10.20452/pamw.15463

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  3 in total

Review 1.  IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.

Authors:  Doha Anka Idrissi; Nezha Senhaji; Asmae Aouiss; Loubna Khalki; Youssef Tijani; Nabil Zaid; Fatima Zahra Marhoume; Abdallah Naya; Mounia Oudghiri; Mostafa Kabine; Younes Zaid
Journal:  Arch Pharm Res       Date:  2021-01-04       Impact factor: 4.946

2.  Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.

Authors:  Kader Irak; Mehmet Bayram; Sami Cifci; Gulsen Sener
Journal:  PLoS One       Date:  2021-11-17       Impact factor: 3.240

3.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.